Bolt Biotherapeutics, Inc. (BOLT): Cash & Equivalents
$11.70M
As of 2025-12-31
$12.86M
As of 2026-06-30
+8.2%
3-year compound annual growth
+16.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $11.70M | +62.4% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $7.21M | -33.3% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $10.81M | +16.9% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $9.24M | -66.2% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $27.38M | +394.1% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $5.54M | n/a | 2022-03-30, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $11.70M | +62.4% |
| Adagene Inc. (ADAG) | 2025-12-31 | $74.52M | -12.5% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $19.96M | -18.8% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $199.16M | +39.6% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $46.82M | +22.1% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $13.15M | -50.0% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $1.42B | -47.7% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $37.57M | +31.0% |
| Immunome Inc. (IMNM) | 2025-12-31 | $653.48M | +355.9% |
Compare BOLT, ADAG, ACRS, XENE side by side · Screen every company in Pharmaceutical Preparations ↗